



Product Information

Product ID P3540
CAS No. 372196-77-5

Chemical Name

Synonym PIK-75 HCl

Formula $C_{16}H_{14}BrN_5O_4S \cdot HCl$

Formula Wt. 488.74

Melting Point 221-223 °C


Purity $\geq 98\%$

Solubility Soluble in DMSO(4mg/mL),
DMF
Water Insoluble
Ethanol Insoluble

Store Temp -20 °C

Ship Temp Ambient

Description PIK-75 is an inhibitor of p110 α PI3K that exhibits anticancer and anti-inflammatory activities. In breast cancer cells, PIK-75 inhibits cell motility and adhesion in vitro and in vivo. PIK-75 also enhances glucose-induced insulin secretion. Additionally, PIK-75 inhibits production of TNF- α , IL-6, E-selectin, ICAM-1, and VCAM-1, preventing monocyte-endothelial cell adhesion.



Bulk quantities available upon request

Product ID	Size
P3540	5 mg
P3540	25 mg
P3540	100 mg

References Buchanan CM, Dickson JM, Lee WJ, et al. Oncogenic mutations of p110 α isoform of PI 3-kinase upregulate its protein kinase activity. *PLoS One*. 2013 Aug 1;8(8):e71337. PMID: 23936502.

Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, et al. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic β -cells. *PLoS One*. 2012;7(10):e47381. PMID: 23077605.

Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. *Oncogene*. 2012 Feb 9;31(6):706-15. PMID: 21725367.

Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110 α /gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. *Am J Physiol Cell Physiol*. 2010 Apr;298(4):C929-41. PMID: 20089935.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.